Search Articles
Reproduction permitted for personal use only. For reprints and reprint permission, contact reprints@wistechnology.com.
Digest
Prodesse enters patent agreement with Roche
June 30, 2006
Waukesha, Wis. – Prodesse Inc., a biotechnology company focused on the development and distribution of reagents for the testing of infectious diseases, has entered into an in-vitro diagnostics patent license agreement with Roche, the Basel, Switzerland-based pharmaceutical firm.
Under the agreement, which will be effective July 1, Prodesse receives the right to include Roche enzymes in its products. Prodesse also receives the authority to convey end-user rights, under Roche patents, to its customers with sale of products for the influenza A virus, influenza B virus, and other viruses.
Related stories
• Prodesse gets new funding; improves flu assay
• Teresa Esser: Entrepreneurial Profile: Kelly Henrickson, founder of Prodesse, Inc.
Under the agreement, which will be effective July 1, Prodesse receives the right to include Roche enzymes in its products. Prodesse also receives the authority to convey end-user rights, under Roche patents, to its customers with sale of products for the influenza A virus, influenza B virus, and other viruses.
Related stories
• Prodesse gets new funding; improves flu assay
• Teresa Esser: Entrepreneurial Profile: Kelly Henrickson, founder of Prodesse, Inc.
Comments
Abedalrahman dahham responded 2 years ago: #1
Dear sir,
I am postgraduate student study on prevalence of equine influenza in Malaysia. I need information about ELISA kit for detection of antibody for Equine influenza. Please inform me because I need to buy this kit (Elisa and PCR).
I am postgraduate student study on prevalence of equine influenza in Malaysia. I need information about ELISA kit for detection of antibody for Equine influenza. Please inform me because I need to buy this kit (Elisa and PCR).
Add Your Comment
Comment Policy: WTN News accepts comments that are on-topic and do not contain advertisements, profanity or personal attacks. Comments represent the views of the individuals who post them and do not necessarily represent the views of WTN Media or our partners, advertisers, or sources. Comments are moderated and not immediately posted. Your email address will not be posted.
WTN Media cannot accept liability for the content of comments posted here or verify their accuracy. If you believe this comment section is being abused, contact edit@wistechnology.com.
Advertisement
Most Popular Stories
Advertisement
Featured EventsMore…
- Apr 14 BioForward Professional Development Series - Managing Performance
- Apr 21 BioForward Professional Development Series - Project Management Essentials
- Apr 21 5th Annual Wisconsin Stem Cell Symposium -- The Road to Stem Cell Applications: Bioprocessing, Safety and Preclinical Evaluation
- Apr 22 - 23 9th Annual International Bioethics Forum - Taking the Measure of the Magic Mirror: Toward a Science of Consciousness
- Apr 22 UW-Madison IT Business Alignment Course
- May 19 - 20 Digital Healthcare Conference
- Oct 4 - 6 2010 World Stem Cell Summit
More Stories
- CIO drives IT business value with new perspective on processes
- Perspective matters when considering IT investment budgets
- The National Broadband Plan needs to be fixed -- already
- March Madness: IT Companies head to the big dance
- Theory meets practice in entrepreneurial bootcamp
- Core BTS will transition to new CEO based in Madison
- Measure would force White House, private sector to collaborate in cyber-crisis
- Adding it up: The politics of job creation mathematics in Wisconsin
- Reducing the anxiety of paying online
- 18- to 24-year-olds most at risk for ID theft, survey finds
WTN Media Presents
